Effectively, in Study 1108, when PD-L1 positive tumor cells were considered (Ventana SP263 system), an ORR of 46.7% was reached with durvalumab, versus 22.2% in case of PD-L1 negativity. The gene discussed is CD274; the disease is neoplasm.